April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Evaluation of Candidate Cell Lines Employed to Deliver Different Antiangiogenic Factors Intraocularly Using Encapsulated Cell Technology
Author Affiliations & Notes
  • Cahil McGovern
    Process Development,
    Neurotech USA, Lincoln, Rhode Island
  • Sandy Sherman
    Process Development,
    Neurotech USA, Lincoln, Rhode Island
  • Crystal Cortellessa
    Process Development,
    Neurotech USA, Lincoln, Rhode Island
  • Konrad Kauper
    Process Development,
    Neurotech USA, Lincoln, Rhode Island
  • Michael Rivera
    Process Development,
    Neurotech USA, Lincoln, Rhode Island
  • Melissa Stiles
    Quality Control,
    Neurotech USA, Lincoln, Rhode Island
  • Suzanna Borges
    Process Development,
    Neurotech USA, Lincoln, Rhode Island
  • Vincent Ling
    Biological Sciences,
    Neurotech USA, Lincoln, Rhode Island
  • Bruce Bouchard
    Process Development,
    Neurotech USA, Lincoln, Rhode Island
  • Weng Tao
    Cell and Molecular,
    Neurotech USA, Lincoln, Rhode Island
  • Footnotes
    Commercial Relationships  Cahil McGovern, Neurotech (F); Sandy Sherman, Neurotech (F); Crystal Cortellessa, Neurotech (F); Konrad Kauper, Neurotech (F); Michael Rivera, Neurotech (F); Melissa Stiles, Neurotech (F); Suzanna Borges, Neurotech (F); Vincent Ling, Neurotech (F); Bruce Bouchard, Neurotech (F); Weng Tao, Neurotech (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3230. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cahil McGovern, Sandy Sherman, Crystal Cortellessa, Konrad Kauper, Michael Rivera, Melissa Stiles, Suzanna Borges, Vincent Ling, Bruce Bouchard, Weng Tao; Evaluation of Candidate Cell Lines Employed to Deliver Different Antiangiogenic Factors Intraocularly Using Encapsulated Cell Technology. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3230.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the in vivo performance of Encapsulated Cell Technology (ECT) devices using different cell lines to deliver antiangiogenic factors for periods up to 3 months.

Methods: : Cell lines secreting antiangiogenic factors were constructed using NTC-200 cells. Once stable output from cells was established, candidate cell lines were encapsulated with ECT devices. The devices were manufactured using standard protocols and were pulsed for factor production at 1, 2, 4, and 6 weeks post manufacture. The devices were subsequently analyzed for metabolic activity and then subjected to either total DNA or histological analysis. Devices held for approximately 3 weeks were implanted in rabbit eyes. The duration of the implantation period ranged from 1 to 3 months. Explanted devices were pulsed for antiangiogenic factor release and subjected to histological analysis. The vitreous was collected and analyzed for antiangiogenic factor levels. Device performance and levels of antiangiogenic factors in the vitreous were quantified by Elisa. Cell metabolic activity was determined using the CCK-8 assay (Dojindo). Total DNA was determined using the Hoefer DyNA Quant 200 fluorometer. Histological examination of the devices was performed using standard hematoxylin and eosin staining techniques.

Results: : In vitro stability: The ECT devices released the desired factors and maintained viable cells during the six week evaluation period. Total DNA analysis of devices showed a consistent number of cells was maintained during the six week testing period and histological analysis of device sections showed a high density of healthy cells distributed throughout the device.In vivo performance: Review of clinical observations showed that devices appeared to be well tolerated during the implantation period. Explanted devices contained healthy cells and released consistent levels of the antiangiogenic factor upon explant at 1 and 3 months. Vitreal samples showed that the level of antiangiogenic factor in the vitreous was maintained throughout the implantation period.

Conclusions: : The data suggested that the Encapsulated Cell Technology platform was able to achieve sustained delivery of antiangiogenic factors for periods up to 3 months in rabbits. This technology can deliver other factors for a broad range of indications where long-term treatment is required.

Keywords: retinal degenerations: hereditary 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×